South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
